Please assess the completion status of the following clinical trial:

Trial Title: Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patient with a mature forearm or upper arm access that was created \> 2 months before enrollment in study.~* The patient is ≥ 18 years of age.~* The patient has a reasonable expectation of remaining on hemodialysis for 12 months.~* The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.~* The patient or his/her legal guardian is willing to provide informed consent.~* The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality.~Exclusion Criteria:~* The patient has a known or suspected systemic infection.~* The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.~* The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (\>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.~* The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).~* The patient has known sensitivity to heparin.~* The patient is scheduled for a live donor kidney transplant.~* The patient is enrolled in another investigational study or another access maintenance trial~* The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements.~* Life expectancy is ≤ 24 months.~* The patient has an untreatable allergy to radiographic contrast material.~* The patient is pregnant.~* In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.~* The patient's access is planned to be abandoned within 1 year.~* The patient has indwelling catheters (dialysis, pacemakers, ports).~* The patient has a central vein stent that would lead to jailing of the internal jugular vein.~* The patient experiences angioplasty-induced venous rupture.~* The patient has a flow limiting dissection after angioplasty.~* The patient's hemodialysis access is thrombosed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 'PTA without use of the GORE VIABAHN' (Type: ACTIVE_COMPARATOR): Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
- PTA with covered stent (Type: EXPERIMENTAL): Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues